Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.
Aravive trades on the NASDAQ stock market under the symbol ARAV.
As of December 6, 2023, ARAV stock price declined to $0.14 with 878,597 million shares trading.
ARAV has a beta of 3.91, meaning it tends to be more sensitive to market movements. ARAV has a correlation of 0.07 to the broad based SPY ETF.
ARAV has a market cap of $10.15 million. This is considered a Sub-Micro Cap stock.
Last quarter Aravive reported $1 million in Revenue and -$.12 earnings per share. This beat revenue expectation by $844,000 and exceeded earnings estimates by $.17.
In the last 3 years, ARAV stock traded as high as $9.95 and as low as $.11.
The top ETF exchange traded funds that ARAV belongs to (by Net Assets): VTI, VXF, IWC, ITOT.
ARAV has underperformed the market in the last year with a price return of -90.9% while the SPY ETF gained +15.4%. ARAV has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -9.1% and -4.6%, respectively, while the SPY returned +1.6% and +0.3%, respectively.
ARAV support price is $.13 and resistance is $.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARAV stock will trade within this expected range on the day.